| A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group. | |
| | |
MedLine Citation:
|
PMID: 7766740 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Lansoprazole is a new proton pump inhibitor which produces prolonged decrease of gastric acidity. The aim of this study was to compare lansoprazole to a standard dose of ranitidine in the treatment of patients with reflux oesophagitis. METHODS: Two hundred and forty-seven patients with erosive oesophagitis were randomly assigned to 8 weeks of treatment with either 30 mg lansoprazole once daily or 150 mg ranitidine twice daily. RESULTS: Two hundred and forty-two patients were included in the analysis. Lansoprazole (30 mg) daily, healed oesophagitis in 92.1% of patients after 8 weeks of treatment. This was significantly superior to 150 mg ranitidine b.d.s. which healed oesophagitis in 69.9% of patients (P < 0.001). Relief of reflux symptoms was superior with lansoprazole to that with ranitidine. Both lansoprazole and ranitidine were well tolerated with no serious drug-related adverse events noted. CONCLUSION: Lansoprazole, 30 mg once daily, is highly effective and safe in the short-term treatment of erosive oesophagitis. |
| | |
Authors:
|
M Robinson; B Sahba; D Avner; N Jhala; P A Greski-Rose; D E Jennings |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: Alimentary pharmacology & therapeutics Volume: 9 ISSN: 0269-2813 ISO Abbreviation: Aliment. Pharmacol. Ther. Publication Date: 1995 Feb |
Date Detail:
|
Created Date: 1995-07-03 Completed Date: 1995-07-03 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8707234 Medline TA: Aliment Pharmacol Ther Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 25-31 Citation Subset: IM |
Affiliation:
|
Oklahoma Foundation for Digestive Research, University of Oklahoma Health Center, Oklahoma City 73104, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
2-Pyridinylmethylsulfinylbenzimidazoles Administration, Oral Alcohol Drinking Anti-Ulcer Agents / administration & dosage, adverse effects, therapeutic use* Caffeine / administration & dosage Double-Blind Method Drug Evaluation Esophagitis, Peptic / drug therapy* Female Gastroscopy H(+)-K(+)-Exchanging ATPase / antagonists & inhibitors* Humans Longitudinal Studies Male Omeprazole / administration & dosage, adverse effects, analogs & derivatives*, therapeutic use Ranitidine / administration & dosage, adverse effects, therapeutic use* Smoking |
| Chemical | |
Reg. No./Substance:
|
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 103577-45-3/lansoprazole; 58-08-2/Caffeine; 66357-35-5/Ranitidine; 73590-58-6/Omeprazole; EC 3.6.1.10/H(+)-K(+)-Exchanging ATPase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pantoprazole versus omeprazole in the treatment of acute gastric ulcers.
Next Document: Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicent...